Full text

Turn on search term navigation

© 2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Nasopharyngeal carcinoma is a rare disease in Western countries. Nevertheless, its incidence in China, Singapore, and other Eastern countries reaches 20 cases per 100,000 people. Being an extremely chemo- and radiosensitive disease, upfront treatment often consists in the association of intensity-modulated radiation therapy and concurrent cisplatin. Unfortunately, about 20% of the patients suffer from a radioresistant disease which recurs after upfront therapy. For these patients, mainly available therapeutic options consist in systemic therapy, in particular poly-chemotherapy. In those showing a single locoregional recurrence, chemotherapy is not considered to be the preferred approach and other different strategies may be employed. Re-irradiation and surgery are strategies that are always used more often, albeit related to high risk of morbidity. Immunotherapy and targeted therapy, such as heavy ions-based re-irradiations, are experimental but very intriguing options.

Details

Title
Management of recurrent nasopharyngeal carcinoma: current perspectives
Author
Perri, F; G Della Vittoria Scarpati; Caponigro, F; Ionna, F; Longo, F; Buonopane, S; Muto, P; M Di Marzo; Pisconti, S; Solla, R
Pages
1583-1591
Section
Review
Publication year
2019
Publication date
2019
Publisher
Taylor & Francis Ltd.
e-ISSN
1178-6930
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2229306965
Copyright
© 2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.